We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+13.4%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$10.9B
AUM Growth
+$1.67B
(+18%)
Cap. Flow
+$806M
Cap. Flow
% of AUM
7.42%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
678
New
211
Increased
171
Reduced
126
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ERF
Enerplus Corporation
ERF
|
+$91.2M |
| 2 |
TE Connectivity
TEL
|
+$81.6M |
| 3 |
Palo Alto Networks
PANW
|
+$78.9M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$75.6M |
| 5 |
Honeywell
HON
|
+$70.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$113M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$88.1M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$70.1M |
| 5 |
Synopsys
SNPS
|
+$64.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.5% |
| 2 | Technology | 22.75% |
| 3 | Industrials | 9.82% |
| 4 | Energy | 8.34% |
| 5 | Consumer Discretionary | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
GE HealthCare
GEHC
$31.8B
| $6.82M | 0.06% |
+75,000
| New | +$6.24M |
|
|
INZY
327
DELISTED
Inozyme Pharma
INZY
| $6.8M | 0.06% |
888,067
+588,067
| +196% | +$3.23M |
|
328
ODDITY Tech
ODD
$624M
| $6.76M | 0.06% |
+155,627
| New | +$6.72M |
|
329
Nkarta
NKTX
$164M
| $6.76M | 0.06% |
+625,129
| New | +$6.5M |
|
330
Alibaba
BABA
$304B
| $6.67M | 0.06% |
+92,210
| New | +$6.76M |
|
331
Reddit
RDDT
$29B
| $6.65M | 0.06% |
+134,810
| New | +$7.38M |
|
332
Editas Medicine
EDIT
$445M
| $6.64M | 0.06% |
895,000
-401
| -0% | -$3.33K |
|
333
Jack in the Box
JACK
$331M
| $6.52M | 0.06% |
95,157
-19,099
| -17% | -$1.44M |
|
334
ON Semiconductor
ON
$18.6B
| $6.28M | 0.06% |
+85,413
| New | +$6.54M |
|
335
Clorox
CLX
$12.8B
| $6.09M | 0.06% |
+39,747
| New | +$5.93M |
|
336
Phathom Pharmaceuticals
PHAT
$679M
| $6.02M | 0.06% |
566,439
-529,682
| -48% | -$4.5M |
|
|
JBIO
337
Jade Biosciences
JBIO
$1.35B
| $5.91M | 0.05% |
+5,714
| New | +$4.36M |
|
|
LSXMA
338
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $5.9M | 0.05% |
198,647
-177,242
| -47% | -$5.33M |
|
339
Sea Limited
SE
$68B
| $5.89M | 0.05% |
+109,596
| New | +$5.04M |
|
340
Mirum Pharmaceuticals
MIRM
$5.74B
| $5.86M | 0.05% |
233,267
-19,996
| -8% | -$550K |
|
341
Zevra Therapeutics
ZVRA
$702M
| $5.86M | 0.05% |
+1,009,617
| New | +$6.21M |
|
342
Wave Life Sciences
WVE
$1.19B
| $5.85M | 0.05% |
948,444
-443,117
| -32% | -$2.22M |
|
343
Shake Shack
SHAK
$2.83B
| $5.8M | 0.05% |
55,738
-133,137
| -70% | -$11.7M |
|
344
Pacific Biosciences
PACB
$363M
| $5.77M | 0.05% |
1,537,433
-316,674
| -17% | -$1.85M |
|
345
Legend Biotech
LEGN
$3.73B
| $5.61M | 0.05% |
100,007
+7
| +0% | +$422 |
|
|
GRVY
346
GRAVITY
GRVY
$425M
| $5.55M | 0.05% |
73,101
-10,377
| -12% | -$726K |
|
347
Granite Ridge Resources
GRNT
$615M
| $5.5M | 0.05% |
846,913
-319,821
| -27% | -$1.88M |
|
348
MacroGenics
MGNX
$255M
| $5.38M | 0.05% |
+365,425
| New | +$5.52M |
|
349
Bausch + Lomb
BLCO
$5.84B
| $5.36M | 0.05% |
309,965
+474
| +0.2% | +$7.36K |
|
350
Viking Therapeutics
VKTX
$3.88B
| $5.36M | 0.05% |
+65,308
| New | +$2.91M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Woodline Partners held 678 positions worth $10.9B, up 18% from $9.2B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Woodline Partners deployed $806M of net new capital in Q1 2024, opening 211 new positions and adding to 171 existing holdings. Its largest new stake was Enerplus Corporation: 5,602,613 shares worth $110M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $110M trimmed.
- Woodline Partners's largest Q1 2024 buy was Enerplus Corporation: 5,602,613 shares worth $110M.
- Woodline Partners added most to TE Connectivity in Q1 2024, an estimated $81.6M increase.
- Woodline Partners's biggest Q1 2024 reduction was AbbVie, cutting an estimated $110M.
- Woodline Partners fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $113M.
- Woodline Partners's ten largest holdings make up 14% of its $10.9B portfolio in Q1 2024.
- Woodline Partners opened 211 new positions and closed 150 in Q1 2024.
- Woodline Partners's portfolio value rose 18% quarter-over-quarter to $10.9B.
Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.